ArticleOncotarget2017
Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis.Frontiers in oncology · 2019Pooled it
- New Standards in the Treatment of Advanced Metastatic Melanoma: Immunotherapy and BRAF-Targeted Therapies as Emerging Paradigms.Current pharmaceutical design · 2026Review
- Identification of m6A methyltransferase-related WTAP and ZC3H13 predicts immune infiltrates in glioblastoma.Scientific reports · 2025Article
- Peripheral immune biomarkers associated with response to adoptive cell therapy with tumor infiltrating lymphocytes.Clinical and experimental immunology · 2025Article
- Prospects and challenges of CAR-T cell therapy combined with ICIs.Frontiers in oncology · 2024Review
- Article
- LAG-3 Inhibitors: Novel Immune Checkpoint Inhibitors Changing the Landscape of Immunotherapy.Biomedicines · 2023Review
- Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the Future.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Review
- The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition.Therapeutic advances in medical oncology · 2023Review
- Nature vs. Nurture: The Two Opposing Behaviors of Cytotoxic T Lymphocytes in the Tumor Microenvironment.International journal of molecular sciences · 2021Review
- Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types.Journal for immunotherapy of cancer · 2021Article
- Nanobodies Enhancing Cancer Visualization, Diagnosis and Therapeutics.International journal of molecular sciences · 2021Review
- Lymphocyte expansion in bioreactors: upgrading adoptive cell therapy.Journal of biological engineering · 2021Review
- LAG-3 is expressed on a majority of tumor infiltrating lymphocytes in pediatric Hodgkin lymphoma.Leukemia & lymphoma · 2021Article
- Article
- CTLA-4 blockade boosts the expansion of tumor-reactive CD8Scientific reports · 2020Article
- Melanoma-associated antigen-A and programmed death-ligand 1 expression are associated with advanced urothelial carcinoma.Cancer immunology, immunotherapy : CII · 2019Article
- TIL therapy and anti-CTLA4: can they co-exist?Oncotarget · 2019Article
- Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Article
- A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Article
Corrections and comments
- Erratum issuedCorrection: Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma.2018 · Rosenkrantz, Lisbet Hölmich [corrected to Hölmich, Lisbet Rosenkrantz]
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTumour infiltrating lymphocyte (TIL) based adoptive cell therapy (ACT) is a promising treatment for patients with advanced melanoma. Retrospective studies suggested an association between previous treatment with anti-CTLA-4 antibodies and long term survival after subsequent ACT. Thus, we hypothesized that treatment with anti-CTLA-4 antibodies can induce favourable changes to be detected in TILs.
resultsExpanded T cells from Ipilimumab treated patients had a higher proportion of cells expressing CD27, intracellular CTLA-4, TIM-3 and LAG-3. In addition, broader and more frequent T cell responses against common tumour antigens were detected in patients treated with Ipilimumab as compared to anti-CTLA-4 naïve patients. MATERIALS AND
methodsExpanded TILs were obtained from patients with advanced melanoma who had received Ipilimumab in the previous six months, or had not received any type of anti-CTLA-4 antibody. T cell specificity and expression of phenotypic and exhaustion markers were scrutinized as well as functional properties.
conclusionsIpilimumab may induce tumor-infiltration of T cells of a more naïve phenotype expressing markers related to activation or exhaustion. Additionally, Ipilimumab may increase the frequency of T cells recognizing common tumour associated antigens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.